Results 201 to 210 of about 37,731,658 (401)

Molecular imaging predicts trastuzumab‐deruxtecan (T‐DXd) response in head and neck cancer xenograft models

open access: yesMolecular Oncology, EarlyView.
Trastuzumab‐deruxtecan, a HER2‐targeting antibody‐drug conjugate, shows promising antitumor activity in head and neck squamous cell carcinoma with low HER2 expression. In vitro and in vivo studies demonstrated dose‐dependent cell death and tumor growth reduction in low HER2‐expressing cell lines, which correlated with drug accumulation measured using a
Abdullah Bin Naveed   +8 more
wiley   +1 more source

Efficacy and safety of vismodegib in advanced basal-cell carcinoma.

open access: yesNew England Journal of Medicine, 2012
A. Sekulic   +18 more
semanticscholar   +1 more source

Appearance of basal cell carcinoma on untreated capillary malformation. [PDF]

open access: yesAn Bras Dermatol
Buchroithner C   +5 more
europepmc   +1 more source

Genomics‐led approach to drug testing in models of undifferentiated pleomorphic sarcoma

open access: yesMolecular Oncology, EarlyView.
GA text Genomic data from undifferentiated pleomorphic sarcoma patients and preclinical models were used to inform a targeted drug screen. Selected compounds were tested in 2D and 3D cultures of UPS cell lines. A combination of trametinib and infigratinib was synergistic in the majority of UPS cell lines tested, which was further confirmed in an ex ...
Piotr J. Manasterski   +19 more
wiley   +1 more source

Basal cell skin cancer, version 1.2016: Clinical practice guidelines in oncology

open access: yes, 2016
C. Bichakjian   +29 more
semanticscholar   +1 more source

Mitochondrial dysfunction drives basal cell hyperplasia in eosinophilic oesophagitis. [PDF]

open access: yesGut
Morimoto M   +29 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy